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Abstract
Pathogen reduction is a viable approach to ensure the continued safety of the blood supply against emerging pathogens.
However, the currently licensed pathogen reduction techniques are ineffective against non-enveloped viruses such as
hepatitis A virus, and they introduce chemicals with concerns of side effects which prevent their widespread use. In this
report, we demonstrate the inactivation of both enveloped and non-enveloped viruses in human plasma using a novel
chemical-free method, a visible ultrashort pulsed laser. We found that laser treatment resulted in 2-log, 1-log, and 3-log
reductions in human immunodeficiency virus, hepatitis A virus, and murine cytomegalovirus in human plasma, respectively.
Laser-treated plasma showed $70% retention for most coagulation factors tested. Furthermore, laser treatment did not
alter the structure of a model coagulation factor, fibrinogen. Ultrashort pulsed lasers are a promising new method for
chemical-free, broad-spectrum pathogen reduction in human plasma.
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Introduction
Pathogen reduction (PR) is an ideal strategy to combat
emerging pathogens and ensure the continued safety of blood
products. However, the PR techniques that are currently in use for
clinical blood products have limitations that preclude their
widespread use (for reviews, see [1–3]). The solvent-detergent
(SD) method [4,5], which inactivates enveloped viruses by
disrupting lipid membranes, was discontinued in the United
States due to an association with unexpected thromboses in some
patients [4,6]. Light-activated photochemicals such as methylene
blue [7,8] and amotosalen [9,10], which inactivate pathogens
through crosslinking, also involve introducing chemicals with
concerns of side effects. Such side effects include allergic reactions
(in the case of methylene blue) and the generation of antibodies
against the treated blood product (in the case of the chemical S-
303) [1], as well as the concern of unknown, unpredictable long-
term effects that invariably arise with any administered compound.
Furthermore, all of the above mentioned methods are ineffective
against non-enveloped viruses such as hepatitis A virus (HAV) [6].
Ultrashort pulsed (USP) lasers have recently emerged as an
attractive potential technique for pathogen inactivation [11]. The
visible USP laser PR technology does not involve potentially toxic
or carcinogenic chemicals. Visible USP lasers are non-ionizing and
do not covalently modify proteins, thereby reducing concerns of
neoantigen formation. Furthermore, USP laser treatment can
inactivate a broad spectrum of viruses and bacteria [11–14],
including non-enveloped viruses that are traditionally difficult to
inactivate. Under these treatment conditions, the structure of
bovine serum albumin protein was well preserved [14].
In this work we demonstrate inactivation of human immuno-
deficiency virus (HIV), HAV, and murine cytomegalovirus
(MCMV) in human plasma using a USP laser operating at a
wavelength of 425 nm. These pathogens are structurally repre-
sentative of a broad range of viruses including enveloped RNA
virus (HIV), non-enveloped RNA virus (HAV), and enveloped
DNA virus (MCMV). MCMV serves as a surrogate for human
herpesviruses including HCMV. We used MCMV for this study
because it is not infectious to humans, allowing us to conduct more
detailed studies in a less restrictive environment. MCMV is also
readily available in our lab and straightforward to analyze on the
bench; more importantly, as an enveloped DNA virus, MCMV
serves structurally as a model for clinically relevant enveloped
DNA viruses which include Hepatitis B virus, HCMV, and
poxviruses. The USP laser technology has been shown to
inactivate viruses through mechanical means; in other words,
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inactivation by the USP laser is most dependent on the structure of
a virus.
Furthermore, we assess the function of coagulation factors in
treated plasma versus untreated plasma after USP laser irradia-
tion.
Materials and Methods
Femtosecond laser irradiation
The excitation source employed in this work was a diode-
pumped continuous wave mode-locked Ti-sapphire laser (Trestles-
100, Del Mar Photonics, USA). The laser produced a continuous
train of 60 fs pulses at a repetition rate of 80 MHz. The output of
the second harmonic generation system of the Ti-sapphire laser
was used to irradiate the sample. The excitation laser was chosen
to operate at a wavelength of l =425 nm and with an average
power of approximately 120 mW. This laser wavelength was
chosen because we have recently demonstrated that it was capable
of efficiently inactivating enveloped/non-enveloped, DNA/RNA
viruses including HIV, MCMV, murine norovirus, encephalo-
myocarditis virus, and human papillomavirus [11]. It has a pulse
width of full-width at half maximum=100 fs. A lens was used to
focus the laser beam into a spot within the sample volume.
Samples were laser-irradiated for 90 min. A magnetic stirring
device was used to facilitate exposure of the sample to the laser
beam. Irradiation was carried out at 22uC and with the single laser
beam excitation. After laser irradiation, samples were immediately
stored at 280uC.
Viruses and infectivity assays
HIV inactivation. HIV stock was propagated in MT-4 cells
following transfection of HeLa cells with pNL4-3 plasmid (both
MT-4 cells an pNL4-3 were kind gifts of Dr. Kuan-Teh Jeang).
Approximately 46106 reverse transcriptase (RT) units of NL4-3
stock was added to pooled normal plasma (George King
Biomedical, Inc., Overland Park, KS). The infected plasma was
placed into each of 6 glass vials for transport to the laser lab. Each
of the 3 vials containing a stir bar was laser-irradiated as described
above. During the treatment time, a vial serving as a room
temperature control was placed in a beaker in the same room.
During each treatment time, 4 of the 6 vials remained on ice.
When each of 3 vials had been irradiated, all 6 vials were
transported back to the HIV lab, where they were stored at 2
80uC until used in a Multinuclear Activation Galactosidase
Indicator (MAGI) assay. For the MAGI assay, the MAGI cells
(U373-MAGI-CXCR4 CEM, catalog #3596, contributed by Dr.
Michael Emerman) were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, Bethesda, USA. The standard MAGI assay protocol
was followed. Briefly, plasma/virus mixture was added to MAGI
cells, incubated for 48 h, fixed with 4% paraformaldehyde for 2 h,
and X-gal (Teknova, USA, Cat # X1205) staining was visualized.
Three irradiated samples, three room temperature control
samples, and the original virus stock were used in the assay. The
final dilution factor for treated samples and controls was 1:2
compared to the original virus stock dilution used in the assay.
HAV inactivation. HAV stock was obtained from the
American Type Culture Collection (Manassas, VA) as VR1402,
a cell culture-adapted cytopathic clone of strain HM-175 that was
originally designated as HM-175/18f. The virus was propagated
on fetal rhesus monkey kidney (FRhK-4) cells as previously
described [15]. The HAV stock was stored at 270uC in DMEM
(Gibco, Grand Island NY) with 10% fetal bovine serum (FBS)
(Gibco) prior to use. To partially purify HAV, the virus was
pelleted at 490,0006g for 6 h, followed by resuspension of the
HAV in human plasma (George King Biomedical Inc., Overland
Park, KS) and filtration through a 0.1 mm filter. Samples of
human plasma alone or human plasma spiked with HAV were
laser-irradiated as described above. Plaque assay was performed
by making an initial 100-fold dilution followed by 10-fold serial
dilutions made in Earle’s balanced salt solution (Gibco) and
infecting 100-mm dishes confluent with FRhK-4 cell and infecting
with 2 ml of virus dilution as described previously [16]. After 2 h,
the plates were overlaid with DMEM medium with 5% FBS, and
1% agarose (Sigma-Aldrich, St. Louis, MO). At 17 days post-
inoculation, HAV was inactivated by 10% formaldehyde treat-
ment, the agarose overlay was removed, and HAV plaques were
visualized by crystal violet staining (Fisher Scientific, Kalamazoo,
MI).
MCMV inactivation. Murine embryonic fibroblast 10.1
(MEF 10.1) cells [17] (a generous gift from Dong Yu, Washington
University School of Medicine, St Louis, MO) were cultured in
Dulbecco’s Modified Eagle Medium (DMEM), supplemented with
10% FBS, 1 mM sodium pyruvate, and nonessential amino acids.
GFP-expressing MCMV virus (hereafter referred to as ‘‘MCMV’’)
was generated as previously described [18]. To produce viral
stocks, MEF 10.1 cells were infected with MCMV at a low
multiplicity of infection. Cell supernatants were harvested 24 h
post-infection after 100% cytopathic effect and cleared of cell
debris by centrifugation. Extracellular virions were pelleted by
ultracentrifugation with sorbitol cushion and resuspended in
phosphate-buffered saline (PBS). Samples of human plasma alone
or human plasma spiked with MCMV were laser-irradiated as
described above. Viral titers were determined using a median
tissue culture infectious dose (TCID50) assay, as previously
described [13]. Briefly, MEF 10.1 cells were seeded into 96-well
plates at a density of 1.256105 cells/ml and incubated overnight.
Cells were approximately 80% confluent at the time of infection.
Laser-treated or control (untreated) viruses were serially diluted
and added to cells, which were incubated for 4 days. Viral titers
were determined on day 4 post-infection by scoring each well for
GFP-positive cells using a fluorescent microscope.
Coagulation factor assays
To evaluate the activity of coagulation factors in plasma with or
without USP laser treatment, we performed standard coagulation
factor assays [19]. Plasma samples derived from the same lot of
pooled normal human plasma (George King Biomedical, Inc.)
were kept untreated or laser-treated as described previously.
Factor (F) II, FV, FVII, FVIII, FIX, FX, FXI, FXII, and
fibrinogen were evaluated in Barnes-Jewish Hospital Laboratory,
St. Louis, MO. Assays were completed on the IL ACL TOP 700,
according to the manufacturer’s protocols contained within the
package inserts (Instrumentation Laboratories Company, Bedford,
MA). Plasma levels of FII, FV, FVII, and FX were determined
using functional assays based on the prothrombin time with
human plasma immunodepleted of FII, FV, FVII, or FX.
Similarly, plasma levels of FVIII, FIX, FXI, and FXII were
determined using the activated partial thromboplastin time with
human plasma immunodepleted of FVIII, FIX, FXI, and FXII.
Plasma deficient in FII, FV, FVII, FVIII, FIX, FX, FXI, or FXII
consisted of human plasma that was immunodepleted of the
individual coagulation factors, and were purchased from Instru-
mentation Laboratories Company. HemosIL RecombiPlasTin 2G
and HemosIL SynthASil (Instrumentation Laboratories Company)
were additional reagents used in the assay. Fibrinogen level was
determined by a quantitative assay based on the Clauss method
Laser Pathogen Reduction
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[20,21] using Q.F.A. Thrombin (Bovine) reagent (Instrumentation
Laboratories Company).
Protein gel electrophoresis
To evaluate protein aggregation of samples with or without
USP laser treatment, we employed gel electrophoresis analysis. For
SDS-PAGE, control (untreated) or laser-treated samples contain-
ing equivalent quantities of plasma were boiled in loading buffer
(dH2O (47.5%), 0.5 M Tris pH 6.8 (12.5%), glycerol (10%), SDS
(20%), b-mercaptoethanol (5%), and bromophenol blue (5%))
under reducing conditions, and separated on a Mini-Protean
TGX 10% precast polyacrylamide gel (Bio-Rad, Hercules, CA).
For native PAGE, control (untreated) or laser-treated samples
containing equivalent quantities of plasma were separated on the
10% gel under non-denaturing conditions. Protein bands were
visualized with Coomassie blue staining (LabSafe Gel Blue, G-
Biosciences).
Fibrinogen protein preparation
Purified human fibrinogen was obtained from Haemtech
Technologies, Inc (Essex Junction, VT). For protein structure
characterization measurements, fibrinogen solutions (2.5 mg/ml)
were prepared by dissolving pure, lyophilized peptide in PBS
buffer which was filtered with a 0.02 mm Whatman Anotop25
filter. The actual concentration was checked by measuring the
absorption of the sample with a Cary50 UV-Vis spectrophotom-
eter (Agilent, Inc., Santa Clara, CA), using an extinction
coefficient of fibrinogen at 280 nm of 5.126105 M21 cm21.
Dynamic light scattering (DLS), circular dichroism (CD) and
absorbance measurements were carried out immediately before
and after irradiation of the sample.
Dynamic light scattering measurements
To determine the effect of USP laser treatment on the
aggregation of fibrinogen protein, we employed dynamic light
scattering analysis. Before and after irradiation, fibrinogen samples
were centrifuged at 12,0006g for 15 min to clear them from dust,
and 5 ml aliquots were taken to measure the DLS signal of the
sample. Autocorrelation functions of the scattered intensity at 90u
scattering angle were collected at 25uC with a 5 sec acquisition
time, using a Wyatt Technology DynaPro NanoStar with a
658 nm, 120 mW GaAs linearly polarized laser. Measurements of
fibrinogen were done in a 1 ml MicroCuvette (Wyatt Technology
Corp., Santa Barbara, CA), previously calibrated with clear water.
Data were analyzed using Wyatt Technology Dynamics 7
software, using a regularization fit method to determine hydrody-
namic radii of fibrinogen from the autocorrelation functions.
Circular dichroism measurements
To examine laser-induced alterations in the secondary structure
of fibrinogen protein, circular dichroism measurements were
made. Immediately before and after irradiation, an aliquot of the
fibrinogen sample was diluted (1:20 for the 2.5 mg/ml sample and
1:10 for 1.5 mg/ml and 0.6 mg/ml samples) and transferred to a
1 mm quartz cuvette (Starna Cells, Atascadero, CA, USA) and
circular dichroism spectra were measured at room temperature
using J-710 spectropolarimeter (Jasco Instruments, Easton, MD).
Far UV spectra from 200 nm to 250 nm were obtained by
averaging over eight scans, with a 1 nm bandwidth, 0.5 nm pitch
and 50 nm/min scan speed, and then buffer subtracted. Fibrin-
ogen concentration was estimated from the absorption spectra of
undiluted samples, measured before and after laser irradiation.
These values were used to convert CD signals to mean residue
ellipticity (MRE). We note that a slight decrease in the signal
amplitude was observed each time the samples were transferred
from one container to another. This was consistent with the
expected loss of protein due to adsorption of fibrinogen to the
surface of containers [22].
Statistics
Quantitative experiments were performed in triplicate. Differ-
ences between mean titers of control and laser-treated virus were
analyzed by Student’s t-test using Graphpad Prism and Microsoft
Excel software. p,0.05 was used as a threshold for statistical
significance.
Results
USP laser treatment inactivates viruses in human plasma
For this study, we chose HIV and HAV as medically significant
enveloped and non-enveloped RNA viruses, respectively, and we
chose MCMV as a representative enveloped DNA virus whose
results could be extrapolated to relevant human pathogens such as
cytomegalovirus and hepatitis B virus. To demonstrate that the
USP laser treatment can inactivate viruses in plasma, aliquots of
HIV, HAV, or MCMV were spiked into human plasma and
treated with the laser. USP laser treatment of virus-spiked plasma
samples resulted in approximately 2-log, 1-log, and 3-log
reductions in HIV, HAV, and MCMV titers, respectively
(Figure 1A–C). The reduction in HAV titers after USP laser
treatment exceeds that achieved by the currently licensed SD and
amotosalen techniques [6]. It is anticipated that further optimi-
zation of laser parameters such as wavelength (i.e., operating at
wavelengths where absorption by bilirubin/hemoglobin are
minimal) would yield greater inactivation of viruses. These data
indicate that USP laser treatment can achieve clinically meaning-
ful reduction of viruses in human plasma.
The function of human plasma proteins is preserved after
USP laser treatment
To determine the functional integrity of human plasma after
USP laser treatment, we laser-treated human plasma alone using
the same conditions used to inactivate the viruses. After treatment,
samples were subjected to standard coagulation assays. Human
coagulation factors in laser-treated plasma showed preservation of
activity comparable to that achieved with other clinically tested PR
methods [6]. The percent retention of individual coagulation
factors after laser treatment relative to control is shown in Table 1.
With the exception of Factor VII, the activities of all the plasma
proteins were near or within the normal reference range. Relative
to non-irradiated sample, Factors II, V, VII, IX, and X showed $
90% retention. Factor XII and fibrinogen showed $70%
retention. Factors VIII and XI were the most sensitive and
showed 68% and 54% retention, respectively. Although Factor II
activity was increased by 20% relative to control (p = 0.04), the
value still fell within the normal reference range, and similar small
increases in the activity of certain factors after treatment using
current PR methods have been reported, potentially due to the
intrinsic variation in the assay2. As an example, riboflavin
treatment was previously shown to increase the measured activity
of Factor XIII to 113% the control value [6]. Therefore, we did
not attribute clinical significance to the observed increase in Factor
II activity. Interestingly, the USP laser treatment caused a
dramatic enhancement in the measured activity of Factor VII in
plasma (Table 1). This effect could either be direct (i.e., laser-
induced structural changes in Factor VII protein) or indirect (i.e.,
laser-induced damage to factor(s) that inhibit Factor VII activity).
Laser Pathogen Reduction
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We believe that the latter scenario is more likely, since it is difficult
to envision how USP laser treatment could directly increase the
activity of Factor VII protein by altering its native structure.
Therefore, a plausible explanation is that the USP laser treatment
may cause damage to Factor VII inhibitor(s) that are present in
human plasma (such as tissue factor pathway inhibitor, TFPI),
which leads to an apparent ‘‘enhancement’’ in measured Factor
VII activity. It is expected that further optimization of laser
parameters such as wavelength (i.e., operating at wavelengths
where absorption by bilirubin and/or hemoglobin are minimal)
would yield greater preservation of plasma proteins. These data
demonstrate that USP laser irradiation retains coagulation factor
activities in an acceptable range for clinical translation.
USP laser treatment does not induce detergent-resistant
aggregation in human plasma proteins
To determine the effects of laser treatment on human plasma
proteins, we analyzed control (untreated) and laser-treated plasma
by SDS-PAGE (Figure 2A, left panel). Both control and laser-
treated plasma contained some intrinsic level of detergent-resistant
aggregates as evidenced by the presence of low-mobility protein
complexes that are unable to migrate through the gel. However,
USP laser treatment of plasma did not cause any significant
qualitative increase in these aggregates. We were also unable to
find evidence for any laser-induced increase in detergent-resistant
aggregates in plasma by native PAGE (Figure 2B). These data
suggest that USP laser treatment does not induce detergent-
resistant aggregation among plasma proteins.
The secondary structure and aggregation state of
purified human fibrinogen are unaltered after USP laser
treatment
As shown in Table 1, the function of some coagulation factors
was reduced after laser treatment. In particular, the function of
fibrinogen, which is the coagulation factor that occurs at the
highest concentration in plasma (,2–4 mg/ml) among the factors
tested, was reduced to 73% of control. To determine if direct,
laser-induced change in protein structure and/or aggregation state
of the protein itself was responsible for this reduction in function,
we analyzed the structure and aggregation state of purified human
fibrinogen protein at physiological concentration (2.5 mg/ml) after
USP laser treatment using circular dichroism and dynamic light
scattering analysis, respectively.
We found no evidence for laser-induced alterations in the
secondary structure of fibrinogen by circular dichroism measure-
ments (Figure 3). Furthermore, we did not observe any significant
laser-induced aggregation of fibrinogen protein by dynamic light
scattering, as evidenced by near-identical proportions of monomer
Figure 1. Inactivation of viruses in plasma using a USP laser. Human plasma containing HIV (A), HAV (B), or MCMV (C) were treated with the
USP laser. For the HIV-spiked plasma, viral titer was assessed by plaque assay in MAGI cells. For the HAV-spiked plasma, viral titer was assessed by
plaque assay in fetal rhesus monkey kidney cells. For the MCMV-spiked plasma, viral titer was assessed by TCID50 assay in murine embryonic
fibroblast cells. Results are representative of triplicate experiments and are shown as means 6 SEM.
doi:10.1371/journal.pone.0111673.g001
Table 1. Retention of coagulation factor activity for USP laser-treated plasma.
Coagulation factor Control plasma Laser-irradiated plasma Normal reference range % retention after treatment
Fibrinogen (mg/dl) 21864 158.562.5 170–400 73
Factor II (IU/ml) 0.8260.02 0.9860.03 0.75–1.30 120
Factor V (IU/ml) 0.8460.01 0.8060.06 0.50–1.25 95
Factor VII (IU/ml) 0.9260.01 2.2260.23 0.50–1.75 241
Factor VIII (IU/ml) 0.7260.01 0.4960.01 0.50–1.60 68
Factor IX (IU/ml) 1.0160.01 0.9660.09 0.55–1.60 95
Factor X (IU/ml) 1.0260.03 1.0460.03 0.60–1.60 102
Factor XI (IU/ml) 1.0160.01 0.5560.09 0.60–1.40 54
Factor XII (IU/ml) 0.9060.00 0.6960.02 0.45–1.70 77
doi:10.1371/journal.pone.0111673.t001
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in both control and laser-treated groups (Table 2). We note that
these values represent the percentage of scattered intensity from
monomers (i.e. species with hydrodynamic radius of 12 nm). In
both the controls and the irradiated samples, the remaining 40%
of intensity came from a much larger species, with a hydrody-
namic radius around 100 nm. Because large aggregates scatter
much more than monomers, these values indicate that roughly
90% of the protein mass was monomeric (assuming that the
Figure 2. SDS-PAGE and native PAGE analysis of control and USP laser-treated plasma proteins. (A) On the left is shown the SDS-PAGE
of control and laser-treated plasma; on the right, for comparison, is shown the SDS-PAGE of laser-treated MCMV virus adapted from Tsen et al [13]
(reprinted with permission from the Society of Photo-Optical Instrumentation Engineers). Control (untreated) or USP laser-treated plasma were boiled
in reducing buffer and separated on a 10% gel. Proteins were visualized by Coomassie blue stain. The solid arrow indicates the location of low
mobility detergent-resistant aggregates; the dotted arrow indicates missing band(s) corresponding to aggregated proteins. (B) Native PAGE of
control and laser-treated plasma. Control (untreated) or USP laser-treated plasma were separated on a 10% gel. Proteins were visualized by
Coomassie blue stain. Arrows indicate location of low mobility detergent-resistant aggregates.
doi:10.1371/journal.pone.0111673.g002
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aggregates are spherical). Similar results were obtained with
fibrinogen at lower concentrations (1.5 mg/ml and 0.6 mg/ml).
These findings indicate that USP laser treatment does not directly
cause alterations in the secondary structure or aggregation state of
purified fibrinogen protein itself when the protein is treated at
physiological or sub-physiological concentrations.
Discussion
In this report we demonstrate inactivation of representative
viruses in plasma using a visible USP laser, with preservation of
plasma proteins. Although we achieved significant reductions in
virus, we note that the laser inactivation efficiency for viruses in
plasma is decreased relative to that for viruses in phosphate-
buffered saline (PBS) [13,23]. This is likely due to the reduced
penetration of light through plasma, which is less transparent than
PBS. This can be remedied by designing a laser treatment
chamber that is sufficiently thin (,1 mm depth) to maximize light
transmission. For example, in a continuous-flow treatment
scenario (for example using a syringe pump), a tube or capillary
with a small depth would ensure more complete exposure of the
sample to the laser light. In future studies, we estimate that the use
of more powerful commercially available lasers would enable
focused spot sizes on the order of millimeters. Coupled with
continuous flow systems, this could provide a plasma treatment
efficiency on the order of ,100 ml per minute which would bring
the technology closer to clinical plausibility.
After USP laser treatment, most coagulation factor activities
were retained in the range of 70–100% control. Typically, in the
field of blood transfusion the acceptable retention percentage of
protein activities for PR methods in human plasma is about 70%
[6]. For example, methylene blue (MB)-treated plasma has been
used extensively in the clinic, and this method reduces the activity
of several proteins to this threshold (fibrinogen, 65%; FVIII, 67%)
[6]. Other clinically employed methods such as amotosalen have
similar damage profiles. The proteins (except Factor XI) in human
plasma treated with our USP laser technology were retained at
around 70% activity or above (Table 1); therefore, it should be
considered to be meeting this requirement. We believe that this
non-invasive USP laser technology will have minimal side effects
partly because of the nature of the inactivation mechanism by the
USP laser irradiation, and partly because no chemicals are
introduced in the treatment process. Therefore, using human
plasma treated with the USP laser irradiation would be safer
compared with other PR methods. Although the level of
preservation is in the range of other established PR methods,
there is potential for improvement. Human plasma contains
bilirubin, a molecule that absorbs light at the 425 nm wavelength
we used for laser PR [24]. This absorption leads to intermolecular
energy transfers that may negatively affect the structure of
bilirubin-associated proteins in plasma. Since viruses in PBS alone
are efficiently inactivated by USP laser treatment [12–14,23,25–
27], bilirubin is clearly not required for laser PR. Thus it is possible
that by selecting a different wavelength where absorption by
bilirubin is minimized, the detrimental effects of the USP laser
treatment on plasma proteins can be mitigated. For example, use
of near-infrared excitation wavelengths above 700 nm will
improve the penetration depth of light and minimize absorption
of light by plasma proteins for effective pathogen inactivation.
Previous data supported a model whereby the USP laser
inactivates enveloped viruses such as MCMV by laser-driven
excitation of vibrational modes within viral capsids, resulting in
aggregation of densely-packed tegument and capsid proteins
[13,28]. The laser treatment caused the formation of large,
strongly bound aggregates of viral capsid/matrix proteins that did
not readily dissociate under denaturing or reducing conditions,
which we term ‘‘detergent-resistant aggregates’’ [13]. Figs. 2A and
2B demonstrate that USP laser treatment does not induce
detergent-resistant aggregates in human plasma. On the other
hand, our previous gel results on the control and USP laser-treated
MCMV in buffered solution, which is shown in the right panel of
Fig. 2A, indicated that USP laser irradiation caused detergent-
resistant aggregates, leading to the inactivation of MCMV.
Ideally, it is the gel analysis for the MCMV in human plasma
that needs to be made. However, we have found that the signature
signal of MCMV was overwhelmed by the tremendously large
background contributions from the various components present in
the human plasma in the gel analysis of the MCMV spiked in
human plasma. As a result, the analysis is too complicated to be
reliably made. Therefore, we chose to analyze the best possible
experiments next to the ideal one, namely purified MCMV in
buffered solution. Because the analysis of the gel results on the
purified MCMV is not the ideal one, as a compromise, we make a
reasonable assumption that the effects of USP laser treatment on
enveloped viruses such as MCMV are the same in the buffered
solution as in the human plasma. This assumption is reasonable
because it is supported by our observations that MCMV is
efficiently inactivated by the USP laser irradiation both in the
buffered solution and in human plasma. Under this assumption, it
can be shown that the protein aggregation induced by the USP
laser irradiation is a plausible mechanism for our experimental
observations that the USP laser efficiently inactivates viruses while
retaining protein activities in the human plasma. The protein
aggregation induced by the USP laser irradiation has been
demonstrated to be density-dependent [13]; namely, the more
closely the proteins are packed, the larger the probability of
protein aggregation. Because the protein density is significantly
higher within the MCMV virion than in human plasma, it is
expected that protein aggregation by the USP laser irradiation
would be much more probable within the MCMV than in the
Table 2. Dynamic light scattering measurements on the aggregation state of fibrinogen.
Fibrinogen concentration Sample % monomer
2.5 mg/ml Control fibrinogen 60+/23
Laser-treated fibrinogen 61+/27
1.5 mg/ml Control fibrinogen 63+/24
Laser-treated fibrinogen 56+/29
0.6 mg/ml Control fibrinogen 65+/27
Laser-treated fibrinogen 57+/210
doi:10.1371/journal.pone.0111673.t002
Laser Pathogen Reduction
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human plasma, leading to the efficient inactivation of MCMV but
retention of the majority of coagulation factor activities in human
plasma.
We also note that that ideally, it is the fibrinogen within human
plasma that needs to be analyzed. However, we have found that
the CD and DLS analyses for fibrinogen in human plasma are too
complicated to be reliably made due to the presence of
background contributions from other components present in the
human plasma. Therefore, we chose to analyze the best possible
experiments next to the ideal one, namely the CD and DLS of
purified fibrinogen. Because the CD and DLS analysis of purified
fibrinogen is not the ideal one, as a compromise, we choose not to
make a definitive conclusion based on the CD and DLS results on
purified fibrinogen. Instead, we conclude that the CD and DLS
results on purified fibrinogen provide a possible clue to explain
why the USP laser irradiation preserves the majority (73%) of the
fibrinogen activity in human plasma.
We were unable to correlate the observed reduction in plasma
protein function with any changes in the secondary structure or
aggregation state of the proteins. There are two potential
explanations for this observation. Firstly, the USP laser may cause
only minimal structural damage to these proteins at a level
undetectable by circular dichroism, dynamic light scattering, and
SDS-PAGE. In this case, more sensitive methods such as nuclear
magnetic resonance may be required to elucidate these changes.
Alternatively, the function of plasma proteins might be indirectly
inhibited by laser-induced damage to other factors in plasma that
promote the coagulation activity of these proteins. Indeed, the
absorption of laser light by other molecule(s) present in plasma,
such as bilirubin, might lead to energy transfer from these
molecule(s) to closely bound/closely associated proteins. Studies on
the effect of bilirubin on plasma protein preservation after USP
laser treatment are currently underway.
Visible USP laser treatment provides important advantages in
the field of PR. The USP laser technology does not involve
introducing potentially toxic or carcinogenic chemicals, and thus
avoids possible side effects from such additives. Unlike the SD and
amotosalen methods, which have seen significant clinical use in
Europe, USP laser treatment can inactivate non-enveloped
viruses. In addition, USP lasers are non-ionizing and do not
disrupt covalent bonds, thereby reducing the potential to generate
immunogenic neoantigens in blood products. Furthermore, USP
lasers are environmentally friendly, circumventing the need to
incorporate undesirable compounds such as mercury which is used
in UV lamps.
Such qualities make USP lasers a promising potential method
for sterilization not only of blood products, but of pharmaceuticals,
biologicals, and cell culture as well. As described above, the ISRS
inactivation mechanism of USP lasers is very likely to leave small
molecule pharmaceuticals and soluble recombinant proteins
structurally undamaged. In addition, we have previously shown
that a therapeutic window exists for which viruses and bacteria can
be inactivated without causing death in human cells [12]. Studies
are currently ongoing to conclusively demonstrate these applica-
tions.
Conclusion
We have performed PR experiments on three representative
viruses in human plasma by using a visible USP laser. Our
experimental results demonstrate that it is feasible to use this novel
USP laser technology to inactivate viruses while retaining the
function of coagulation factors in human plasma at a clinically
acceptable level. This is the first proof-of-concept study of PR in
human plasma using USP lasers. This chemical-free USP laser
technology has potential advantages over current PR techniques.
Figure 3. Structural analysis of control and laser-treated fibrinogen protein. Control (untreated) or laser-treated fibrinogen protein was
analyzed by circular dichroism. The red line indicates the CD spectrum of control fibrinogen, while the dotted black line indicates laser treated
fibrinogen. The spectra (in Mean Residue Ellipticity, rescaled for concentration) show virtually complete overlap.
doi:10.1371/journal.pone.0111673.g003
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